The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an eosinophilic phenotype, according to a press release from GSK.Depemokimab ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Eosinophilia may be an important ...

Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & ...

Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with ...

asthma, lungs Mepolizumab was associated with reductions in eosinophil levels and asthma exacerbations, as well as improvements in quality of life in uncontrolled severe eosinophilic asthma. HOUSTON — ...

December 9, 2009 (Buenos Aires, Argentina) — Serum levels of eosinophil-derived neurotoxin (EDN) might indicate the severity of asthma better than serum levels of eosinophil cationic protein (ECP) or ...

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 and older with severe eosinophilic asthma, making it the first biologic ...

Some people with very severe asthma symptoms have a condition called eosinophilic asthma. People with this type of asthma may need to use inhaled medicines along with a newer type of medicine that is ...

LONDON, United Kingdom — For patients with severe uncontrolled eosinophilic asthma, the anti-interleukin (IL)-5 pathway can be targeted with the investigational biologic agent benralizumab, two phase ...

Dupilumab (interleukin-4Rα; antibody binds to interleukin-4Rα, inhibiting interleukin-4 and interleukin-13 signaling in hematopoietic cells [e.g., B cells, CD4+ helper T cells, and eosinophils], ...